$XOMA
XOMA Royalty Corp

2022 Q4 Form 10-Q Financial Statement

#000155837022016142 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $1.486M $451.0K
YoY Change -95.87% -52.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.571M $4.794M
YoY Change 36.71% 12.67%
% of Gross Profit
Research & Development $28.00K $29.00K
YoY Change -33.33% -3.33%
% of Gross Profit
Depreciation & Amortization $97.00K $4.000K
YoY Change 9600.0% 100.0%
% of Gross Profit
Operating Expenses $7.696M $4.823M
YoY Change 37.92% 12.56%
Operating Profit -$4.372M
YoY Change 30.7%
Interest Expense $214.0K $194.0K
YoY Change -149.77% -117.78%
% of Operating Profit
Other Income/Expense, Net $5.000K $194.0K
YoY Change -117.78%
Pretax Income -$5.991M -$4.178M
YoY Change -120.01% -5.82%
Income Tax -$15.00K
% Of Pretax Income
Net Earnings -$7.344M -$4.178M
YoY Change -124.61% -5.82%
Net Earnings / Revenue -494.21% -926.39%
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$0.64 -$0.48
COMMON SHARES
Basic Shares Outstanding 11.45M 11.45M
Diluted Shares Outstanding 11.45M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.73M
YoY Change 12.52%
Cash & Equivalents $57.83M $78.29M
Short-Term Investments $443.0K
Other Short-Term Assets $997.0K
YoY Change -77.27%
Inventory
Prepaid Expenses
Receivables $0.00 $16.00K
Other Receivables $0.00
Total Short-Term Assets $61.25M $79.74M
YoY Change -36.83% 6.5%
LONG-TERM ASSETS
Property, Plant & Equipment $7.000K $8.000K
YoY Change -46.15% -46.67%
Goodwill
YoY Change
Intangibles $15.15M
YoY Change
Long-Term Investments
YoY Change
Other Assets $260.0K $260.0K
YoY Change -13.62% -13.62%
Total Long-Term Assets $79.13M $66.39M
YoY Change 13.71% 19.34%
TOTAL ASSETS
Total Short-Term Assets $61.25M $79.74M
Total Long-Term Assets $79.13M $66.39M
Total Assets $140.4M $146.1M
YoY Change -15.72% 11.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $524.0K $985.0K
YoY Change -51.12% 64.72%
Accrued Expenses $1.293M
YoY Change -14.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.818M $5.425M
YoY Change -47.42% -16.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $10.38M
YoY Change 51805.0%
Total Long-Term Liabilities $10.38M
YoY Change 51805.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.818M $5.425M
Total Long-Term Liabilities $10.38M
Total Liabilities $16.37M $15.81M
YoY Change -33.7% -16.45%
SHAREHOLDERS EQUITY
Retained Earnings -$1.182B -$1.176B
YoY Change 1.47% -1.57%
Common Stock $86.00K $86.00K
YoY Change 1.18% 1.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.0M $130.3M
YoY Change
Total Liabilities & Shareholders Equity $140.4M $146.1M
YoY Change -15.72% 11.98%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$7.344M -$4.178M
YoY Change -124.61% -5.82%
Depreciation, Depletion And Amortization $97.00K $4.000K
YoY Change 9600.0% 100.0%
Cash From Operating Activities -$3.890M -$3.663M
YoY Change -112.69% 19.12%
INVESTING ACTIVITIES
Capital Expenditures $15.25M
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $26.00K
YoY Change -100.0% -100.37%
Cash From Investing Activities -$15.25M $26.00K
YoY Change 154.12% -100.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.322M -1.260M
YoY Change -8.13% -17.97%
NET CHANGE
Cash From Operating Activities -3.890M -3.663M
Cash From Investing Activities -15.25M 26.00K
Cash From Financing Activities -1.322M -1.260M
Net Change In Cash -20.46M -4.897M
YoY Change -188.17% -57.82%
FREE CASH FLOW
Cash From Operating Activities -$3.890M -$3.663M
Capital Expenditures $15.25M
Free Cash Flow -$19.14M
YoY Change -162.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4178000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4436000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11128000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14046000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5546000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5804000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15232000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17238000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11447000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11311000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11400000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11279000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5546000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5804000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15232000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17238000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11447000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11311000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11400000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11279000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11315263
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11450823
dei Entity Central Index Key
EntityCentralIndexKey
0000791908
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q3 xoma Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q3 xoma Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q3 xoma Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2022Q3 xoma Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2022Q3 xoma Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2022Q3 xoma Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39801
dei Entity Registrant Name
EntityRegistrantName
XOMA Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2154066
dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Powell Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 310
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
204-7200
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11450823
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78285000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93328000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2049000
CY2022Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
443000
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
774000
CY2022Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
16000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
209000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
997000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
613000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
79741000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
96973000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
73000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2022Q3 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
66049000
CY2021Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
69075000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
260000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
301000
CY2022Q3 us-gaap Assets
Assets
146131000
CY2021Q4 us-gaap Assets
Assets
166562000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
985000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1072000
CY2022Q3 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
1208000
CY2021Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
525000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
91000
CY2022Q3 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
75000
CY2021Q4 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
8075000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
85000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
195000
CY2022Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
1704000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1641000
CY2022Q3 xoma Accrued Preferred Stock Dividend Current
AccruedPreferredStockDividendCurrent
1368000
CY2021Q4 xoma Accrued Preferred Stock Dividend Current
AccruedPreferredStockDividendCurrent
1368000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5425000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12967000
CY2022Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
10381000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
11685000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34000
CY2022Q3 us-gaap Liabilities
Liabilities
15806000
CY2021Q4 us-gaap Liabilities
Liabilities
24686000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11450823
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11315263
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
86000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
85000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1306606000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1307030000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1176416000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1165288000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
130325000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141876000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146131000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
166562000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
550000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3300000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1094000
CY2022Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
426000
CY2021Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
390000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1241000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1121000
CY2022Q3 us-gaap Revenues
Revenues
451000
CY2021Q3 us-gaap Revenues
Revenues
940000
us-gaap Revenues
Revenues
4541000
us-gaap Revenues
Revenues
2215000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
129000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4794000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4255000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15620000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14922000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4823000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
4285000
us-gaap Operating Expenses
OperatingExpenses
15745000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
130325000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
86424000
us-gaap Operating Expenses
OperatingExpenses
15051000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4372000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3345000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11204000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12836000
us-gaap Interest Expense Debt
InterestExpenseDebt
461000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-300000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
194000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1091000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
76000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-449000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4178000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4436000
us-gaap Net Income Loss
NetIncomeLoss
-11128000
us-gaap Net Income Loss
NetIncomeLoss
-14046000
CY2022Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1368000
CY2021Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1368000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
4104000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3192000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5546000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5804000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15232000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17238000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11447000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11311000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11400000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11279000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141876000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
633000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
85000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
978000
CY2022Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2280000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
139924000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
189000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
45000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
836000
CY2022Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4670000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
134956000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
806000
CY2022Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4178000
xoma Payments Related To Purchase Of Royalty Rights And Other Commercial Payment Rights
PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
20500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4974000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
388000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
90000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2898000
CY2021Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
707000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7373000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
81720000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
594000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
17000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
768000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37140000
CY2021Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1424000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2237000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
116578000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
779000
CY2021Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4436000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
111584000
us-gaap Profit Loss
ProfitLoss
-11128000
us-gaap Profit Loss
ProfitLoss
-14046000
us-gaap Share Based Compensation
ShareBasedCompensation
2620000
us-gaap Share Based Compensation
ShareBasedCompensation
4445000
xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
85000
xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
90000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
7000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
6000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
200000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-300000
xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-127000
xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-119000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-330000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-482000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-193000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
255000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-1526000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
343000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
526000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
596000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
955000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-91000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-144000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-133000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1241000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1121000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-6000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8989000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7964000
us-gaap Payment For Contingent Consideration Liability Investing Activities
PaymentForContingentConsiderationLiabilityInvestingActivities
8000000
xoma Receipts Related To Purchase Of Royalty Rights And Other Commercial Payment Rights
ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
3026000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20500000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
40000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17000
us-gaap Payments Of Dividends
PaymentsOfDividends
4104000
us-gaap Payments Of Dividends
PaymentsOfDividends
2131000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3248000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2373000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1492000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1398000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
479000
xoma Repayments Of Long Term Debt Excluding Extinguishment Of Debt
RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt
4250000
xoma Repayments Of Long Term Debt Extinguishment Of Debt
RepaymentsOfLongTermDebtExtinguishmentOfDebt
17103000
us-gaap Payments Of Debt Restructuring Costs
PaymentsOfDebtRestructuringCosts
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3129000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14274000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17092000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14190000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95377000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86364000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78285000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72174000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
95000
us-gaap Interest Paid Net
InterestPaidNet
311000
CY2022Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1368000
CY2021Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1368000
xoma Accrued Cost Related To Issuance Of Preferred Stock
AccruedCostRelatedToIssuanceOfPreferredStock
137000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. The Company’s portfolio was built through licensing its proprietary products and platforms from its legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017. The Company’s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of September 30, 2022, the Company had cash and cash equivalents of $78.3 million. Based on the Company’s current cash balance and its ability to control discretionary spending, such as royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.</p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78300000
us-gaap Net Income Loss
NetIncomeLoss
-11128000
us-gaap Net Income Loss
NetIncomeLoss
-14046000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5546000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5804000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15232000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company’s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic and the subsequent global slowdown has led to delays and could result in further delays or terminations of some clinical trials underlying the Company’s RPAs. Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgment. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements.</p>
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
30200000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78285000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93328000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2049000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78285000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95377000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11447000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11311000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11400000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11279000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17238000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
xoma Impairment Of Long Term Royalty Receivable
ImpairmentOfLongTermRoyaltyReceivable
0
CY2021 xoma Impairment Of Long Term Royalty Receivable
ImpairmentOfLongTermRoyaltyReceivable
0
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
55000
CY2022Q3 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
162000
CY2021Q4 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
135000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2022Q3 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
1208000
CY2021Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
525000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
45000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. For the three months ended September 30, 2022, one partner represented 94% of total revenues. For the nine months ended September 30, 2022, four partners represented 44%, 27%, 17% and 11% of total revenues. For the three months ended September 30, 2021, two partners represented 53% and 41% of total revenues. For the nine months ended September 30, 2021, three partners represented 51%, 23% and 23% of total revenues. As of December 31, 2021, one partner represented 100% of the trade receivables, net balance. There were no trade receivables, net balance as of September 30, 2022.</p>
CY2022Q3 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
0
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
555000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
295000
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
461000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4178000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4436000
us-gaap Operating Lease Cost
OperatingLeaseCost
133000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5897000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5512000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5840000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5370000
CY2022Q3 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
66000000.0
CY2021Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
69100000
xoma Royalty And Commercial Rights Acquired
RoyaltyAndCommercialRightsAcquired
0
CY2022Q3 xoma Royalty And Commercial Rights Acquired
RoyaltyAndCommercialRightsAcquired
0
CY2021Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
69075000
CY2022Q3 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
66049000
CY2022Q3 xoma Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q3 xoma Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
52000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
34000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
86000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
85000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
45000
us-gaap Operating Lease Cost
OperatingLeaseCost
133000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
4000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
3000
us-gaap Variable Lease Cost
VariableLeaseCost
9000
us-gaap Variable Lease Cost
VariableLeaseCost
8000
CY2022Q3 us-gaap Lease Cost
LeaseCost
49000
CY2021Q3 us-gaap Lease Cost
LeaseCost
48000
us-gaap Lease Cost
LeaseCost
142000
us-gaap Lease Cost
LeaseCost
141000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2800000
us-gaap Operating Lease Payments
OperatingLeasePayments
151000
us-gaap Operating Lease Payments
OperatingLeasePayments
147000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y5M1D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M1D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11177
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11177
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1572356
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.09
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M10D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10282000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.21
CY2022Q3 xoma Contractual Obligation Estimated Milestone Payments
ContractualObligationEstimatedMilestonePayments
6300000
CY2022Q3 xoma Contractual Obligation Estimated Milestone Payments Number Of Products
ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
1
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1911177
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.64
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M29D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15103000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
222972
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.83
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
128811
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
48600
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
64.55
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1956738
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M15D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10284000
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2021Q3 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q3 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5900000
CY2022Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q3 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001558370-22-016142-index-headers.html Edgar Link pending
0001558370-22-016142-index.html Edgar Link pending
0001558370-22-016142.txt Edgar Link pending
0001558370-22-016142-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220930.xsd Edgar Link pending
tmb-20220930x10q.htm Edgar Link pending
tmb-20220930xex10d1.htm Edgar Link pending
tmb-20220930xex10d1003.jpg Edgar Link pending
tmb-20220930xex10d1009.jpg Edgar Link pending
tmb-20220930xex10d2.htm Edgar Link pending
tmb-20220930xex10d2003.jpg Edgar Link pending
tmb-20220930xex10d2009.jpg Edgar Link pending
tmb-20220930xex10d3.htm Edgar Link pending
tmb-20220930xex10d4.htm Edgar Link pending
tmb-20220930xex10d4002.jpg Edgar Link pending
tmb-20220930xex31d1.htm Edgar Link pending
tmb-20220930xex31d2.htm Edgar Link pending
tmb-20220930xex32d1.htm Edgar Link pending
tmb-20220930_def.xml Edgar Link unprocessable
tmb-20220930_pre.xml Edgar Link unprocessable
tmb-20220930_lab.xml Edgar Link unprocessable
tmb-20220930x10q_htm.xml Edgar Link completed
tmb-20220930_cal.xml Edgar Link unprocessable